<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03934034</url>
  </required_header>
  <id_info>
    <org_study_id>NTM-KOREA</org_study_id>
    <nct_id>NCT03934034</nct_id>
  </id_info>
  <brief_title>A Prospective Registry For Patients With Non-Tuberculous Mycobacterial (NTM) Pulmonary Disease in Korea.</brief_title>
  <acronym>NTM-KOREA</acronym>
  <official_title>A Prospective Registry For Patients With Non-Tuberculous Mycobacterial (NTM) Pulmonary Disease in Korea.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korean Institute of Tuberculosis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Tuberculosis Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence and prevalence of pulmonary disease due to Non-tuberculous mycobacteria (NTM)
      is increasing worldwide, and this trend has been confirmed in Korea. Treatment of NTM
      pulmonary disease is difficult and usually requires more than two years of long-term
      treatment, and the antibiotic regimens used in treatment vary. Therefore, it is difficult to
      track the natural history of patients with NTM pulmonary disease, to evaluate the treatment
      outcome, and to understand the effect of specific medicines on the outcome. Establishing a
      prospective registry of patients with NTM pulmonary disease is expected to accurately
      evaluate the progress, treatment modality, and treatment outcome of NTM pulmonary disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Treatment success rate</measure>
    <time_frame>Through study completion, at 1 year after treatment start at enrollment</time_frame>
    <description>Analysis of treatment success rate according to species of NTM lung disease patients in Korea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the efficacy among different regimens for the treatment of certain species of NTM</measure>
    <time_frame>Through study completion, at 1 year after treatment start at enrollment</time_frame>
    <description>Comparison of the outcomes measured by culture conversion among different regimens for the treatment of certain species of NTM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changing culture results during treatment</measure>
    <time_frame>Through study completion, at 1 year after treatment start at enrollment</time_frame>
    <description>Number of participants with changing culture results during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>Through study completion, at 1 year after treatment start at enrollment</time_frame>
    <description>Number of participants with treatment-related adverse events specifically described in the protocol</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Pulmonary Disease</condition>
  <condition>Pulmonary Infection</condition>
  <condition>Non-Tuberculous Mycobacterial Pneumonia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with NTM lung disease initiating treatment at each hospital participating in the
        study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of NTM pulmonary disease.

          2. The causative agent of NTM pulmonary disease includes: M. avium complex, or M.
             abscessus subspecies abscessus, or M. abscessus subspecies massiliense, or M.
             kansasii.

          3. Patients who starts new treatment (those who have previous history of treatment are
             eligible)

        Exclusion Criteria

          1. Patients who have been treated for more than 4 weeks.

          2. The causative agent of NTM pulmonary disease is none of M. avium complex, M. abscessus
             subspecies abscessus, M. abscessus subspecies massiliense, or M. kansasii.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>April 30, 2019</last_update_submitted>
  <last_update_submitted_qc>April 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jae-Joon Yim</investigator_full_name>
    <investigator_title>Professor, Pulmonary and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>NTM</keyword>
  <keyword>Registry</keyword>
  <keyword>Pulmonary infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

